Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

NEXT STORY
Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure
PREV STORY
Teleflex Announces Tenth Anniversary of GuideLiner® Catheter Product Line
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy

PHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ...

author_avatar
NASDAQ Market News

TRACON Pharmaceuticals Announces Positive Results from TRC105 and TRC102 Clinical Trials at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Median PFS greater than 12 months with continued durable complete responses observed in angiosarcoma ...

author_avatar
NASDAQ Market News

Precision Therapeutics, Inc. Signs Letter of Intent to Purchase Remainder of Helomics Corporation Shares

author_avatar
NASDAQ Market News